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MicroAbstract 
 
Besides its effects on bone metastases, zoledronic acid has many other antitumor effects.  
This randomized phase II trial studied the interest of adding zoledronic acid to neoadjuvant 
chemotherapy in breast cancer with serum VEGF as primary endpoint. We observed a trend of 
neoadjuvant zoledronic acid to lower serum VEGF. Further studies are needed with longer 
follow-up and additional relevant endpoints.  
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Abstract 
 
Introduction: Neoadjuvant chemotherapy has become the treatment of choice for locally 
advanced breast cancer. Zoledronic acid (ZA) is a bisphosphonate initially used in the treatment 
of bone metastases due to its anti-bone resorption effect. Anti-tumour effects of ZA, such as the 
inhibition of cell adhesion to mineralized bone or the anti-angiogenic effect, have been 
demonstrated. However, the clinical significance of these effects remains to be determined. 
Materials and Methods: We undertook a multicenter open-label randomized trial to analyze the 
value of adding ZA to neoadjuvant chemotherapy in TNM cT2/T3 breast cancer. The primary 
endpoint was the evolution of serum VEGF.  
Results: 24 patients were included in the ZA group and 26 in the control group. Evolution of 
serum VEGF was slightly in favour of ZA at 5.5 months, - 0.7% versus + 7.5%, without reaching 
statistical significance (p 0.52). Secondary endpoints were breast conservation rate (higher with 
ZA, 83.3% vs 65.4%, NS), pathologic complete response (no effect), and circulating tumour 
cells (odds ratio of 0.68 in favour of ZA, 95% CI [0.02- 24.36]). No cases of jaw necrosis or 
severe renal failure were observed in both groups.  
Conclusion: ZA is an anti-tumour drug of interest with multiple effects on tumour biology, and 
larger trials with longer follow-up would be of interest including additional endpoints such as 
relapse and survival rates.  
 
Trial Registration: ClinicalTrials.gov, Identifier: NCT01367288.  
 
Keywords: Breast cancer - Locally advanced breast cancer- Zoledronic acid - Neoadjuvant 
treatment- VEGF 
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Introduction 
 
Zoledronic acid (ZA, Zometa°) is a bisphosphonate that has shown to have both direct and 
indirect anti-tumoural effects. Inhibition of tumour cell adhesion to mineralized bone and further 
inhibition of bone metastases, stimulation of gamma/delta T lymphocyte cytotoxicity, induction 
of tumour cell apoptosis and an anti-angiogenic effect have been demonstrated [1-8].   
The side effects of bisphosphonates are relatively few, out of which we can mention mandibular 
osteonecrosis which is infrequent. We decided to carry out a prospective randomized multicenter 
study, the NEOZOL study, comparing two systemic neoadjuvant treatments in locally advanced 
cancers, chemotherapy with ZA versus chemotherapy alone.  
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Materials and Methods 
 
Patients 
Women aged 18 years and older, with newly diagnosed invasive breast cancer of maximal 
diameter greater than 2 cm, UICC stage IIa, IIb and IIIa, were invited to join the study. 
Multifocal or multicentric tumours and inflammatory cancers were excluded.  
Absence of contraindication to ZA was checked: creatinine clearance < 30ml/min with Cockroft 
or MDRD method, pregnancy or concomitant dental problems.  
 
Study design and procedures 
This is an exploratory multicenter phase IIa clinical trial, randomized controlled (1:1) and open-
label. Two systemic neoadjuvant treatments were evaluated, one with ZA, the other without. 
Nineteen French centres participated in the study. The trial was accepted by the Lyon IV Ethics 
Committee and patients were enrolled after having signed an informed consent. 
 
Enrolment and Randomization 
Work-up included complete physical examination, mammograms, breast sonograms, breast MRI 
and a tumour biopsy to determine the histological status, grade, estrogen and progesterone 
receptors and HER2 status. Minimal biopsy volume was 2 mm3. Patients were checked for 
distant metastases (CT scan in addition to bone scintigraphy or FDG-PET). All patients were 
sent to a specialist for an oral examination and a jaw panoramic x-ray.  
After the assessment was completed, patients were randomly allocated 1:1 to the experimental 
group with ZA or the control group by IWRS. The block randomization method and a 
stratification by SBR grading were used to ensure selection bias and to achieve balance in the 
allocation of treatments arms. 
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Neoadjuvant treatment and follow-up 
Zoledronic acid (ZA, Zometa°, Novartis°) was delivered at the usual dose of 4 mg (in a 15 min 
intravenous infusion) every 3 weeks for a total of 6 injections. In the two arms, neoadjuvant 
chemotherapy was given through a minimum of 6 courses (with a minimum of 3 cycles of 
anthracycline) but did not exceed 8 courses. The interval in between each cycle was 3 weeks. 
The type of chemotherapy was in accordance with protocols in use at each centre, but the 
recommended treatment regimen was the one that demonstrated important efficacy in the 
NSABP B27 trial [9]: 4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide 
(600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) 
every 3 weeks (+/- 2 days). 
Each ZA injection was given just after completion of the chemotherapy cycle. 
Patients with overexpression of HER2 received trastuzumab (Herceptin°, Roche°), for a total of 
one year, starting concomitantly to chemotherapy. Surgery took place after completion of the 
antineoplastic treatment associated with trastuzumab.  
Follow-up visits were planned once every 3 weeks, at the time of a chemotherapy cycle, and at 
surgery (V final). Two additional workups were also planned at mid-treatment and at 
chemotherapy completion, during which breast examination, breast imaging, oral and radiologic 
assessments by a dental specialist were carried out. At mid-treatment, a metallic clip was 
inserted (optional) to further localize the tumour site at the time of surgery. An assessment of 
osteonecrosis of the jaw (ONJ) was carried out at each visit (chemotherapy cycles and the 2 
additional workups). In case of ONJ diagnosis, ZA was stopped permanently and the patient was 
discontinued from the study. Blood samples, used for the dosing inter alia of VEGF, platelet 
count, and creatinine and urine samples were collected at V0, at each chemotherapy cycle, and at 
V final. 
In case of alteration of the renal function, ZA was stopped temporarily and given back only when 
creatinine level dropped down to baseline +/- 10%. 
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In case of tumour progression, patients were withdrawn from the study to receive appropriate 
therapy. 
 
Endpoints 
The primary endpoint was the evolution of serum Vascular Endothelial Growth Factor (VEGF) 
(in pg/mL). VEGF has been shown to be a good marker of neoadjuvant chemotherapy efficacy 
[10-17]. VEGF was measured in the collected blood samples using an ELISA kit (Human VEGF 
Quantikine° Kit DVE-00, R&D systems, Lille, France). 
VEGF levels at V0 and at the first cycle were pooled and will herein be referred as ’baseline’ 
VEGF level. Normal serum VEGF levels ranges from 62 pg/mL to 707 pg/mL (mean 220 
pg/mL). This mainly reflects the platelet VEGF burden released during in vitro clotting of blood 
sample necessary to the serum collection. In order to diminish this range and focus on VEGF 
directly in relation to the tumor activity, i.e. free circulating VEGF not transported by platelets, 
we also analyzed the evolution of the VEGF/platelet count ratio (in pg/106 platelets) as 
previously reported [18]. 
The secondary endpoints were breast conservation rate, pathologic complete response (pCR) 
after final surgery, change in Circulating Tumour Cells (CTC) between V0 and V final, and 
therapeutic complications. Pathologic Complete Response was assessed according to the 
Sataloff’s classifications on primary tumour site and regional lymph nodes (Sataloff’s criteria for 
pCR: TA for tumour and Na or Nb for lymph nodes). Therapeutic complications are reported in 
this article as bucco-dental complications and renal failure, the two main potential side effects of 
ZA. Dedicated oral examination and imaging were carried out in ZA experimental group only; 
thus, bucco-dental complications are reported for the experimental group only. For the 
monitoring of renal function, creatinine clearance (in mL/min) was measured at V0 and V final, 
and at each chemotherapy cycle.  
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Statistical analysis (see Annex for further information) 
As an exploration study, we initially set up the total population of this study to 76 patients and 
then estimated the power we would get with the enrolment of these 76 patients. The outcome of 
interest was the relative change in VEGF levels, that is: (value at V final - value at V0)/value at 
V0. With 76 patients (38 per group), using a two-sided 0.05-level t-test, a 0.35-point difference 
in VEGF relative change between arms will be detected with a power exceeding 95% (with a 
standard deviation of VEGF relative change equals to 0.4065).  
All statistical tests were two-sided. P-value <0.05 was considered to indicate a statistically 
significant difference. The numbers in brackets [] following estimated values indicate their 95% 
confidence intervals. For baseline comparison between arms, Fisher’s exact test and Wilcoxon 
test were respectively performed for categorical and quantitative characteristics. 
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Results 
 
From April 2010 to October 2013, 259 patients were considered for enrolment, 71 were pre-
registered with an informed consent signed, 53 were randomized and ultimately 50 went into 
analysis (Figure 1). The planned size of 76 patients was not achieved despite important 
extension of the enrolment period. The most frequent reason for exclusion, after patient’s 
acceptance of the protocol, was dental examination prior to or at V0 in discordance with the 
protocol. 
Patient characteristics and tumor characteristics are listed in Table 1. We observed more clinical 
and pathologically proven lymph node involvement in the control group (57.7% Vs. 29.2% and 
75% Vs. 60%, respectively). 10 patients were HER2 positive, 2 in the ZA group and 8 in the 
control group. 
Evolution of serum VEGF (figures 3 and 4) 
 
1/ Serum VEGF* 
Median duration of follow-up and between chemotherapy initiation and surgery were 5.7 and 5.4 
months, respectively. At baseline, no statistical difference was observed in serum VEGF levels 
between groups according to the SBR grade, HER2 status, clinical lymph node involvement, HR 
status, menopausal status or the tumor size.  
Figure 2 shows the evolution of VEGF according to treatment arm (N=427 VEGF 
measurements). At baseline, VEGF levels were higher in the ZA group than in the control group, 
but the difference was not significant (p= 0.08). At the beginning of chemotherapy, we observed 
a similar evolution. Afterwards, the evolution of VEGF relatively to the baseline value was 
slightly better in the ZA group at the end of follow up. However, this difference of evolution 
between arms was not statistically significant (p = 0.52). Comparison of AUC (Area Under 
Curve) for the two evolution curves from baseline to 6 months showed no difference (p= 0.21).  
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We did not observe any clear significant effect of ZA on serum VEGF levels through treatment 
according to the menopausal status or the ER status (figure 4).  
 
2/ Serum VEGF /Platelet count ratio* 
 
At baseline, serum VEGF/Platelet count ratio was not different between groups (p= 0.11). 
We observed a regular increase of VEGF/Platelet ratio during treatment in each treatment group 
with linear evolution curves which contrasts with the evolution of VEGF (Figure 3; N=399 
VEGF/platelets count values). Evolution of VEGF/Platelet ratio was slightly in favour of ZA. 
However, the difference between the two groups was not statistically significant, AUC 
comparison for the two evolution curves from baseline to 6 months showed no difference (p= 
0.28). Sub-group analysis according to the menopausal status or the ER status revealed no 
significant difference either (figure 4). 
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Conservation rate 
 
The rate of conservative treatment was higher in the ZA group: 83.3% (20/24 patients) versus 
65.4% (17/26) in the control group, although this difference was not significant (NS, p = 0.2, 
Fisher’s exact test). 
 
Pathologic response * 
No significant effect of ZA on the pCR rate was observed.  
ZA seemed more effective in menopausal women than in pre-menopausal women (OR 4.32, 
95% CI [0.85- 22.07]) on Sataloff’s tumour criteria, and appeared significantly more effective in 
menopausal women than in pre-menopausal women as to the lymph node response (OR 12.06, 
95% CI [1.54- 94.33]). 
As expected, when studying the effects of the treatments on the Sataloff’s tumour criteria 
according to the ER status, we observed that ER+ patients had a significant lesser response 
whatever the treatment arm: OR 0.07, 95% CI [0.01- 0.42]) in the ZA group and OR 0.09, 95% 
CI [0.01- 0.71] in the control group, when compared to ER- patients, but no effect of the ER 
status was observed on the Sataloff’s node criteria. At the same time, we observed a significant 
benefit of trastuzumab on the pathological response on both Sataloff’s criteria (data not shown, 
10 patients only).  
 
Circulating Tumour Cells (CTC)* 
The number of patients with CTC was comparable at V0: ZA: 4/19 and Control: 4/18, and at V 
final: one patient in each arm, ZA had no effect on CTC.  
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Therapeutic complications 
Bucco-dental: 
Bucco-dental signs were observed in 5 patients in the ZA group: 1 patient suffered from dental 
pain, 4 were affected by loose teeth but no cases of osteonecrosis were observed. Two cases of 
stomatitis (grade I and II) were observed in this group.  
Renal:  
No occurrence of severe renal failure (clearance < 30 mL/min) was reported in both groups. A 
creatinine clearance of <60 mL/min was observed during treatment in 4 patients of the ZA group 
and in 3 patients of the control group (NS). One patient of the ZA group showed a creatinine 
clearance of 52 mL/min during treatment, the ZA dose had not been reduced as it should have 
been, with no implication. There were similar increases of the creatinine clearance in both 
groups during treatment, with a mean level of +2% per month in the control group and +1.2% in 
the ZA group (p 0.38). 
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Discussion* 
 
Adjuvant zoledronic acid (ZA) has been proven to reduce bone metastases in addition to 
improving survival in post-menopausal women with early breast cancer [19]. 
Despite these benefits in adjuvant therapy, results from several randomized trials are 
controversial and often failed to reach statistical significance as to any advantage of ZA when 
concomitant to neoadjuvant chemotherapy (NAC). In 2010, Coleman reported results of the 
AZURE trial comparing neoadjuvant chemotherapy alone (n= 103) to chemotherapy and ZA (n= 
102).  ZA proved to have a significant effect on the residual tumour size but pathological 
complete response rates were not different [20]. Similarly, Charehbili in 2014 reported results of 
neoadjuvant ZA + NAC (n= 120) in stage II/III breast cancers with no difference in the 
pathological complete response rate when compared to NAC alone (n= 122), though he observed 
a slight benefit in post-menopausal women [21]. Hasegawa also reported positive effects of 
neoadjuvant ZA (NAC + ZA, n = 93) versus NAC alone (n= 95) in the pathological complete 
response rate, especially for post-menopausal women and in women with triple negative 
tumours, although statistically not significant [22].  
The anti-tumoural effects of ZA are numerous and have been studied for almost 20 years, from 
inhibition of bone metastasis formation, through multiple effects including reduction of bone 
resorption due to osteoclastic activity [23; 24], to further studies that demonstrated implications 
of ZA in tumour cell biology and microenvironment that could affect tumour development not 
only in bone but in breast and in all possible secondary tumour locations as well via stimulation 
of gamma/delta T lymphocyte cytotoxicity, induction of apoptosis, inhibition of proliferation, 
angiogenesis, cell migration and invasion [1-8]. Of interest in breast oncology, these effects 
seem to be related to the estrogen environment, ZA being more effective in post-menopausal 
women [25] and in estrogen receptor negative (ER -) patients [26].  Our study failed to show a 
benefit of ZA for improving the pathologic response in post-menopausal and ER- patients. The 
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main trials that studied ZA in concomitance to neoadjuvant chemotherapy had residual tumour at 
surgery as primary endpoint [20; 21; 22]. We chose blood VEGF level as primary endpoint, as it 
has been shown of interest to assess antitumour treatment efficacy [13]. We did observe only a 
moderate and non-significant advantage of concomitant ZA on the VEGF levels. In a 
randomized study published in 2013, also comparing neoadjuvant ZA plus chemotherapy to 
chemotherapy alone in order to observe the short-term biologic effects of neoadjuvant ZA, 
Winter found that chemotherapy plus ZA was more efficient to reduce VEGF levels than 
chemotherapy alone but only from day 5 to day 21, thereafter the effect was lost [27]. Based on 
those results, much larger studies would be required to achieve detailed assessment of VEGF 
evolution with better precision. 
In concordance with other published trials [20; 22], we failed to show any statistical effect of ZA 
on the residual tumour size at surgery. Conversely, like previously reported [28; 29], we did 
observe a significant effect of concomitant neoadjuvant trastuzumab on tumour shrinkage, even 
if the number of patients treated with trastuzumab was small, suggesting a higher efficiency of 
trastuzumab than ZA on reducing the tumour burden (breast tumour and lymph nodes). A recent 
meta-analysis pooling data from 4 trials that studied neoadjuvant ZA [25] showed no advantage 
of ZA on tumour volume regression overall, but in the post-menopausal women sub-group, ZA 
did show a significant effect on tumour regression (pCR in the breast: 10.8% (chemotherapy 
alone) versus 17.7% (chemotherapy + ZA), OR 2.14, CI [1.01-4.55].  
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Conclusion  
 
ZA is an anti-tumour drug of interest with multiple effects on tumour biology. These effects 
might not be as efficient as trastuzumab at providing fast tumour regression, therefore 
neoadjuvant ZA should be studied in larger trials with longer follow-up with relapse and survival 
rates as endpoints in addition to pathologic response at surgery and serum VEGF levels. 
Moreover, the target population should be post-menopausal women and ER- patients.  
 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
18 
 
Clinical Practice Points* 
 
As the use of neoadjuvant chemotherapy has steadily increased, research studies are needed to 
improve its efficacy. Significant multiple biologic effects of zoledronic acid (ZA) in oncology 
have been reported, suggesting other possible uses of this bisphosphonate in addition to bone 
metastasis inhibition related to its anti-bone resorption properties. Interestingly, these effects 
have been reported to vary according to the menopausal status of the patients and the estrogen 
receptor expression of the tumour. Adverse effects of zoledronic acid rarely occur.  
The main trials that studied ZA in concomitance to neoadjuvant chemotherapy (NAC) had 
residual tumour at surgery as primary endpoint. We chose blood VEGF level as primary 
endpoint, as it has been shown of interest to monitor treatment efficacy in a few previous studies. 
We found that choosing serum VEGF level as primary endpoint to monitor response to neo-
adjuvant therapy is of little interest.  
This study failed to show that adding ZA to NAC would increase tumour shrinkage and allow a 
significant higher rate of pathologic complete response.  
In order to improve the efficacy of NAC, adding drugs of interest like ZA should be considered 
in trials with longer follow-up with recurrence and survival endpoints, in addition to short term 
pCR rates.   
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Annex : Detailed statistics 
 
Sample size calculations 
According to data previously published, the mean expected reduction of this biomarker was  
25 % after neo-adjuvant chemotherapy [10;11;12;13;14;16;17]. 
The study from Colleoni et al. [13] demonstrated in 48 patients that the medial reduction was 
0,75 (post/pre) with a 95% CI of (0.62-0.83) after neoadjuvant chemotherapy. These data 
allowed us to calculate an estimation of the standard deviation of the reduction (application of 
the normal rule and taking account that 95CI =+/- 1.96 x se and that  
se = sd/√n, (n = sample size). Given the poor knowledge about the therapeutic efficiency of 
Zoledronic Acid (ZA), such as the standard deviation of the relative reduction of serum VEGF, it 
was impossible to accurately calculate the power of the statistical tests to be performed. The 
power of the test for the primary endpoint given below is thus only approximate and relies on 
hypotheses that may not be realistic. A preliminary experimental study by Ottewel et al.[30] 
showed that the adjunction of ZA to chemotherapy led to a 60 % reduction of serum VEGF in 
the experimental arm, to be compared with a 25% reduction in the chemotherapy alone group, i.e 
a difference of 35% (60%-25%). As there was no data concerning the standard deviation of the 
reduction with ZA, the same standard deviation as the one from Colleoni’s study [13] has been 
chosen for sample size calculation with expected serum VEGF reductions according to Ottewel 
et al.[30]: 
 
Arm A with ZA : expected reduction 60% 
Arm B without ZA : expected reduction 25 %. 
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As an exploratory study, we set up the total population of this protocol to 76 patients. The table 
below gives the power of the test according to the “true” differences in serum VEGF reduction 
between arm A and arm B. 
 
Differences in serum VEGF reduction between Arm A and Arm B Power of the test 
0.05 0.081 
0.1 0.178 
0.15 0.343 
0.2 0.549 
0.25 0.742 
0.3 0.879 
0.35 (the most probable, see above) 0.954 
0.4 0.986 
0.45 0.996 
0.5 0.999 
 
Following the previous hypothesis, for an expected difference of reduction of 35 % between 
the 2 arms (65 % vs 25 % reduction of serum VEGF), this population of 76 was expected to 
allow us to demonstrate this difference with a power of 95,4 %. 
 
Analysis of VEGF evolution 
For the analysis of the primary endpoint, the logarithm of VEGF levels was modelled using a 
linear hierarchical model to take into account the repetition of measurement per patient. This 
model included as fixed effects: treatment arm, a function of time specific to each arm, treatment 
by trastuzumab (trastuzumab received Vs. not received), and an interaction treatment by 
trastuzumab*time. It was expected that VEGF levels increased after initiation of chemotherapy 
and then decreased several weeks afterwards. To reflect this particular dynamics of VEGF, the 
effect of time was modelled using two restricted cubic splines, one per arm, with 1 interior knot 
set at time t=1.5 month and the two boundary knots set at times t=0 (time of 1st chemotherapy 
cycle) and t=5 months. Treatment by trastuzumab was included in this modelling because: i) 
trastuzumab was shown to be efficient in patients with overexpressed HER2, and ii) proportion 
of trastuzumab treatments differed between the two arms. The hierarchical model further 
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included 4 random effects, one intercept and one-time slope random effects per arm. The 4-
dimension random effect vector was assumed to follow a centered Gaussian distribution with a 
6-parameter variance-covariance matrix (4 variance parameters, one per random effect; one 
intercept-slope covariance per arm; covariance between random effects related to different arms 
were set to 0). Parameters were estimated by maximisation of the likelihood. Difference between 
arms of the dynamics of VEGF level was tested using a likelihood ratio test, by comparison with 
a model that included the same effects as previously described, except that it included only one 
restricted spline of time common to both arms. The fit of the model was checked by assessment 
of residual plots and plots comparing observed and predicted values. Furthermore, two additional 
analyses were carried out to study the evolution of VEGF according to estrogen receptor (ER) 
status and to menopausal status; for each status (ER or menopausal), this was done using a 
similar model, that further included the considered status, an interaction arm*status, and a 
time*arm*status interaction. Wald testing was performed to compare, between arms, the change 
in VEGF levels from baseline to 5.5 months, according to status. The same analyses were 
performed to study the evolution of VEGF/platelet ratio. 
 
Analysis of secondary endpoints 
A Fisher exact test was used for the comparison of breast conservation rate between arms. The 
analysis of the tumour response was performed taking into account all measures of the tumour 
diameter. We did not perform separate analysis per type of measurement (clinical or for one 
imaging technology) because of numerous missing values, which would have yield non-
conclusive or non-interpretable results. Conversely, most patients had at least one clinical or 
radiological measurement. The logarithm of the tumour diameter was modelled using a 
hierarchical TOBIT model with the measurements lower than 0.5 cm being left-censored to 0.5 
cm, the minimum observed positive value, to take into account a floor effect (see, for example, 
[31]). This model included as fixed effect: the type of measurement (clinical Vs. radiological), 
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treatment arm, an indicator for each visit (V0, mid-treatment, and chemotherapy completion), 
and, for each visit, an interaction visit*arm and visit*type of measurement. It included also two 
patient-random effects –intercept and slope- to account for between-subject variable regarding 
baseline tumour size and decrease in tumour size. For the analysis of pCR, the three outcomes 
(Chevallier, Sataloff’s tumor, and Sataloff’s node scores) are ordinary variables with 4 levels. 
For each pCR outcome, analysis was carried out using a logistic regression model for ordinal 
dependent-variables, assuming proportional odds [32]. Each model included the treatment arm 
and treatment by trastuzumab (trastuzumab received Vs. not received). Furthermore, two 
additional analyses were carried out to assess pCR according to estrogen receptor (ER) status 
and to menopausal status; this was done using a similar ordinal model, that further included 
either ER status and an interaction arm*ER status, or menopausal status and an interaction 
arm*menopausal status. For the change in CTC between V0 and V final, a logistic regression 
was carried out to model the probability of presence of CTC. Co-variables included in this model 
were: the treatment arm, the visit (V final Vs. V0) and an interaction arm*visit. Finally, the 
logarithm of the creatinine clearance was modelled using a hierarchical linear model that 
included treatment arm, time, and an interaction arm*time as fixed effects. 4 patient-random 
effects were included, similarly as the random effects for the analysis of primary endpoint.  
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Table 1: Patient and tumour characteristics at V0 
 
  ZA Control  
  N % N % P value 
Inflammatory 
cancer 
All 24  26  0.2359 
No 24  23 88.5 
Yes 0 100 3 11.5 
Multifocal 
cancer 
All 24  26  0.6105 
No 23 95.8 23 88.5 
Yes 1 4.2 3 11.5 
Clinical Lymph 
node invasion 
All 24  26  0.0518 
No 17 70.8 11 42.3 
Yes 7 29.2 15 57.7 
Pathologic 
proven Lymph 
node invasion 
prior to 
treatment 
All 24  26   
No 4 40 3 25 
Yes 6 60 9 75 
Undetermined 14  14  
UICC stage All 24  26  0.1023 
IIB 10 41.7 6 23.1 
IIIA 3 12.5 10 38.5 
IIA > 2cm 11 45.8 10 38.5 
Mean age (years)  51.2 
[35- 68] 
50.5 
[22- 72] 
 
Post-menopausal  9 37.5 13 50  
Clinical mean 
tumor diameter 
(mm) 
 48.4 
[20- 170] 
41.7 
[21- 100] 
0.8167 
Ultrasonographic 
mean tumor 
diameter (mm) 
 31.8 
[13- 63] 
29.5 
[0- 75] 
 
SBR Grade All 24  26  1.0000 
I 1 4.2 1 3.8 
II 12 50 15 50 
III 11 45.8 12 46.2 
Histologic Type All 24  26   
Ductal 21 87.5 24 92.3 
Lobular 2 8.3 2 7.7 
Ductal   and 
Lobular 
1 4.2 0 0.0 
ER All 24  26  0.7598 
Positive 16 66.7 19 73.1 
Negative 8 33.3 7 26.9 
PR All 24  26  1 
Positive 11 45.8 11 42.3 
Negative 13 54.2 15 57.7 
ER Positive or 
PR Positive 
All 24  26  0.7598 
Positive 16 66.7 19 73.1 
Negative 8 33.3 7 26.9 
HER2  All 24  26  0.1498 
Positive 2 9.5 8 30.8 
Negative 19 90.5 18 69.2 
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Figure 1: Randomization diagram 
 
  
Patients pre-included
n = 259
Patients pre-registered
n = 71
Patients randomized
n = 53
Patients included into analysis
n = 50
ZA group
n = 24
Control group
n = 26
Patients excluded after 
randomization
n = 3
Dental contraindication: n = 2
Tumeur size ≤ 2 cm: n = 1
Patients not randomized
n = 18
Patient's refusal: 30%
Dental contraindication: 50%
Patients not included
n = 188
Patient's refusal: 17.6%
Dental contraindication: 10.1%
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Figure 2: Mean Relative Evolution of serum VEGF (percentage) per treatment arm,  
the dotted lines show the estimate 95%CI 
(Patients treated with trastuzumab excluded) 
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Figure 3: Mean Relative Evolution of serum VEGF/ platelet count ratio (percentage) per 
treatment arm, the dotted lines showing the estimate 95%CI 
(Patients treated with trastuzumab excluded) 
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Figure 4: Relative evolution of VEGF and VEGF/Platelet between treatment groups 
according to menopausal and ER status 
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Figure 5: Odds ratio of the effect of the treatment arm on the pathologic response 
(Sataloff’s criteria) according to the menopausal and the ER status; and Odds ratio of the 
menopausal and ER status on the pathologic response (Sataloff’s criteria) according to the 
treatment arm 
 
 
